Puma's U.S. Growth vs. China Royalty Decline: Reinforces Wait Rating

What happened

Puma Biotechnology's U.S. NERLYNX demand is on track for a second consecutive year of growth, supported by guideline inclusion and stable volumes despite rising gross-to-net deductions. However, China royalties have collapsed, falling from $24.4M in Q3 2024 to $2.6M in Q3 2025, driven by reduced partner orders, creating a significant revenue headwind. The company continues to generate positive operating cash flow ($27.4M for 9M 2025) and maintains a strong balance sheet with $94.4M in cash and only $33.3M in debt, allowing it to navigate the royalty shortfall. Pipeline progress with alisertib Phase II trials in breast and lung cancer remains a key medium-term catalyst, with H1 2026 interim data expected to clarify the value of that asset. At a share price of $6.65, the market appears to be pricing in stable U.S. NERLYNX revenue and significant pipeline optionality, leaving limited upside versus downside risks including covenant stress or disappointing data.

Implication

The divergence between U.S. growth and China royalty decline will likely keep revenue growth muted, requiring careful monitoring of royalty run-rate stabilization. If FY2026 guidance shows NERLYNX revenue above $205M with royalties stabilizing above $5M per quarter, the bull case strengthens and the stock could re-rate toward $8-9. Conversely, if gross-to-net deductions exceed 24% or royalties remain depressed, downside to $4.50 becomes plausible, especially if alisertib data disappoint. H1 2026 alisertib interim results are the most important catalyst; positive data could justify a higher multiple, while negative results may relegate Puma to a cash-cow with limited growth. Balance sheet strength provides some cushion, but investors should size positions conservatively given the binary nature of pipeline outcomes and the concentrated revenue base.

Thesis delta

The Fool article reinforces the existing thesis of U.S. NERLYNX stability offset by China royalty weakness, which was already captured in the master report. No material shift is warranted; the WAIT rating remains appropriate given the balanced risk/reward at current prices. The key variables to watch over the next 12-18 months are FY2026 guidance, royalty trajectory, and alisertib data, which will determine whether the stock deserves a higher or lower multiple.